Switching from prescription to over-the-counter medications: A consumer and managed care perspective

Managed Care Interface

Volumn 20, Issue 1, 2007, Pages 42-47

  Pawaskar, Manjiri D ^a   Balkrishnan, Rajesh ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CIMETIDINE; COMMIT; FAMOTIDINE; IBUPROFEN; LORATADINE; MINOXIDIL; NICOTINE GUM; NICOTINE PATCH; NON PRESCRIPTION DRUG; OMEPRAZOLE; RANITIDINE; UNCLASSIFIED DRUG;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG CLASSIFICATION; DRUG COST; DRUG INDICATION; DRUG LEGISLATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEARTBURN; HOSPITALIZATION; HUMAN; INDIGESTION; MANAGED CARE ORGANIZATION; MIGRAINE; NICOTINE REPLACEMENT THERAPY; PRESCRIPTION; REVIEW; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT;

CONSUMER SATISFACTION; DRUGS, NON-PRESCRIPTION; HUMANS; MANAGED CARE PROGRAMS; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 33846439347     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Nordenberg T: Now available without a prescription. FDA Consumer Magazine 1996;40(9):1-2.
2. OTC facts and figures, 2001. Consumer Healthcare Product Association (www.chpa-info.org/chpaportal/pressroom/statistics/otcfactsandfigures.htm), August 21, 2006.
3. Brass EP: Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001;345:810-816.
4. Schulke DG: American Pharmaceutical Association review of literature on prescription to over-the-counter drug switches. Clin Ther 1998;20(suppl C):124-133.
5. Aging and health: The role of self-medication. Consumer Healthcare Product Association (www.chpa-info.org/publications/aging_and_health.asp), August 21, 2006.
6. Bradley C, Blenkinsopp A: Over-the-counter drugs: The future for self-medication. BMJ 1996;312:835-837.
7. Leibowitz A: Substitution between prescribed and over-the-counter medications. Med Care 1989;27:85-94.
8. Hughes CM, McElnay JC, Fleming GF: Benefits and risks of self-medication. Drug Safety 2001;24:1027-1037.
9. Shih YC, Prasad M, Luce BR: The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: A microeconomic analysis. Clin Ther 2002;24:701-716.
10. Rosenau PV: Rx-to-OTC switch movement. Med Care Rev 1994;51:429-466.
11. Over-the-counter human drugs; labeling requirements. Fed Reg 1999;64:13254-13303.
12. The switch process. Consumer Healthcare Product Association (www.chpa-info.org), July 4, 2006.
13. Stuart B, Grana J: Are prescribed and over-the-counter medicines economic substitutes? A study of the effects of health insurance on medicine choices by the elderly. Med Care 1995;33: 487-501.
14. Ray WA, Stein CM, Byrd V, et al: Educational program for physicians to reduce use of nonsteroidal anti-inflammatory drugs among community-dwelling elderly persons: A randomized controlled trial. Med Care 2001;39:425-435.
15. Convington TR: Self-care and nonprescription pharmacotherapy, in: Handbook of Nonprescription Medications, vol. 3. Ed. 12. Washington DC, American Pharmacist Association, 2000; 3-12.
16. Meyer SM: In-home testing and monitoring products, in: Handbook of Nonprescription Medications, vol. 39. Ed. 10. Washington DC, American Pharmacist Association, 1993; 39-47.
17. Roper Starch Worldwide: Self-care in the new millennium: American attitudes toward maintaining personal health and treatment, 2001. Consumer Healthcare Products Association (www.chpa-info.org/NR/rdonlyres/9630d06f-16da- 4c55-b53c-6b9edf25eccf/0/self-care%20posted%20qx%20(appendix).pdf), August 21, 2006.
18. McCarren E: Rx-to-OTC switches: Promises and pitfalls. Med Market Media 1991;9:13-25.
19. Gannon K: Why Rx manufacturers would want to make the switch to OTC. Drug Topics 1989;133(48):48.
20. Hollenbeak CS: The effectif generic competition on prescription to over-the-counter switching. Pharmacoeconomics 1999;16: 661-668.
21. Hutt PB: A legal framework for future decisions on transferring drugs from prescription to nonprescription status. Food Drug Cosm Law J 1982;37:427.
22. Haverkost LF: How industry assesses and picks suitable candidates for switch. Drug Inf J 1985;19:133.
23. Hutt PB: Drugs for self-medication in the future: Their source and the social, political, and regulatory climate. Drug Inf J 1985; 19:195.
24. Juhl RP: Prescription to over-the-counter switch: A regulatory perspective. Clin Ther 1998;20(suppl C):111-117.
25. Francis SA, Barnett N, Denham M: Switching of prescription drugs to over-the-counter status: Is it a good thing for the elderly? Drugs Aging 2005;22:361-370.
26. Whitney DW: Product liability issues for the expanding OTC drug category. Food Drug Law J 1993;48:321.
27. Borger C, Smith S, Truffer C, et al: Health spending projections through 2015: Changes on the horizon. Health Aff 2006; 25(2):w61-73.
28. Smith C, Cowan C, Sensenig A, et al: Health accounts team: Health spending growth slows in 2003. Health Aff 2005;24(1): 185-194.
29. Gurwitz JH, McLaughlin TJ, Fish LS: The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: The case of vaginal antifungal products. Health Serv Res 1995;30:672-685.
30. Lanier B: No prescription needed-no doctor either. Ann Allergy Asthma Immunol 2001;87:1-2.
31. Sullivan PW, Nair KV, Patel BV: The effect of the Rx-to-OTC switch of loratidine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care 2005;11:374-382.
32. Keeler TE, Hu TW, Keith A, et al: The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ 2002;11:389-402.
33. Lipsky MS, Waters T: The "prescription-to-OTC switch" movement: Its effects on antifungal vaginal preparations. Arch Fam Med 1999;8:297-300.
34. Geyer S: Who should pay for the uninsured? Trustee 2004; 57(5):12-15.
35. Jackson L, Trude S: Stand-alone health insurance tax credits aren't enough. Issue Brief Cent Stud Health Syst Change 2001; (41):1-4.
36. Murray E, Lo B, Pollack L, et al: Direct-to-consumer advertising: Physicians' views of its effects on quality of care and the doctor-patient relationship. J Am Board Fam Pract 2003;16:513-524.
37. Chao BA: Evaluating the educational content of direct-to-consumer fulfillment materials. Am J Health Syst Pharm 2005; 62:620-625.
38. FDA launches campaign on OTC pain relief products. FDA Consum 2004;38(2):8.
39. Frequently asked questions about Rx-to-OTC switch. Consumer Healthcare Product Association (www.chpa-info.org/chpaportal/pressroom/faqs/switch.htm), December 21, 2005.
40. Juhl RP: Switching drug products from Rx to OTC status: A benefit to pharmacy practice. US Pharm 2000;25:119-128.
41. Bachrach EE: The PDA's new over-the-counter drug office and advisory committee: An industry perspective. Food Drug Law J 1993;48:563-566.
42. Sullivan PW, Follin SL, Nichol MB: Transitioning the second-generation antihistamines to over-the-counter status. Med Care 2003;41:1382-1395.
43. Fronstin P, Helman R, Greenwald M: Small employers and health benefits: Findings from the 2002 small employer health benefits survey. EBRI Issue Brief 2003;253:1-21.
44. Claritin approval marks significant shift in Rx-to-OTC switches. The Food & Drug Letter. FDA News 2002;666:1-10.
45. Kunz K, Arundell E, Cisternas M, et al: Economic implications of self-treatment of heartburn/non-ulcer dyspepsia with nonprescription famotidine in a managed care setting. J Manag Care Pharm 1996;2:263-271.
46. Gosden T, Forland F, Kristiansen IS, et al: Capitation, salary. fee-for-service, and mixed systems of payment: Effects on the behavior of primary care physicians. Cochrane Database Syst Rev 2000;3:CD002215.
47. Desimone EM: Rx to OTC-special counseling concerns. US Pharmacist 1995;20(1):37.
48. Sansgiry SS, Pawaskar MD: Obstruction of critical information on over-the-counter medication packages by external tags. Ann Pharmacother 2005;39:249-254.
49. Bergen A: Overboard on the over-the-counter. USC Health Magazine (www.usc.edu/hsc/info/pr/hmm/03fall/over.html), Fall 2003.
50. Brok J, Buckley N, Gluud C: Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006; 19(2):CD003328.
51. Bromer MQ, Black M: Acetaminophen hepatotoxicity. Clin Liver Dis 2003;7:351-367.
52. Gyamlani GG, Parikh CR: Acetaminophen toxicity: Suicidal vs. accidental. Crit Care 2002;6:155-159.
53. Landers S: Labels on common OTC pain remedies to include heightened risks. Am Med News 2002;45(38):25-28.
54. Layke J, Lopez P: Gastric cancer: Diagnosis and treatment options. Am Fam Physician 2004;69:1133-1140.
55. Rheingold PD: The expanding liability of the drug manufacturer to the consumer. Food Drug Cosm Law J 1985;40:135.
56. Health care expectations: Future strategy and direction 2005. The National Coalition on Health Care (www.nchc.org/facts/cost.shtml), November 2005.
57. Gianfrancesco F, Manning B, Wang R: Effects of prescription-to-OTC switches on out-of-pocket health care costs and utilization. Drug Benefit Trends 2002;14:13-30,44.
58. 2-blockers. Med Care 1990;28:834-852.
59. 2 antagonists to over-the-counter use. Med Care 1997;35:32-48.
60. Rubin N, Foxman B: The cost-effectiveness of placing urinary-tract- infection treatment over the counter. J Clin Epidemiol 1996;49:1315-1321.
61. Levy S: Here comes the new wave. Drug Topics 2003;147:26.
62. Switch trends: Switch forecast: A switch U.S. legislative proposal. Francesco International (www.rxtootcswitch.com/trends/legis.htm), April 3, 2006.
63. West DS, Johnson JT, Hong SH: A 30-month evaluation of the effects on the cost and utilization of proton-pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. J Manag Care Pharm 2006;12:25-32.
64. Sullivan PW, Nichol MB: The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. Value Health 2004;7:402-412.
65. Rowland C: OTC drugs shift cost burden. The Cincinnati Enquirer (www.enquirer.com/editions/2004/02/08/biz_otc08. html), February 8, 2004.
66. Brushwood DB, Abood RR: A third class of drugs: An overview. Drug Intell Clin Pharm 1985;19:62-66.